OptiNose (OPTN)
(Delayed Data from NSDQ)
$0.76 USD
-0.03 (-4.27%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.75 -0.01 (-1.52%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
OPTN 0.76 -0.03(-4.27%)
Will OPTN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for OPTN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OPTN
OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
Profound Medical (PROF) Surges 6.0%: Is This an Indication of Further Gains?
OPTN: What are Zacks experts saying now?
Zacks Private Portfolio Services
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
Other News for OPTN
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
Optinose announces peer-review publication on EDS-FLU efficacy
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript
Optinose’s XHANCE Poised for Market Expansion and Growth: A Buy Rating Review